Singleplex Immunoassay industry global growth reports of 2023

Market Scenario:

The Global Singleplex Immunoassay Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the Global Singleplex Immunoassay Market is expected to register a CAGR ~ 8.4 % during the forecast period of 2018–2023.

Singleplex immunoassays such as Enzyme-Linked Immunosorbent Assays (ELISA) or western blotting are used sequentially to analyze multiple intracellular and extracellular proteins. Moreover, singleplex immunoassay provides a fast and high-through output solution for gene expression quantification. For instance, Thermo Fisher Scientific’s QuantiGene Singleplex assay is developed to detect original RNA or DNA population using signal amplification.

Numerous factors such as growth in the biotechnology and pharmaceutical sector, increasing adoption of rental immunoassay analyzers, and rising use of immunoassay in oncology fuels the growth of global singleplex immunoassay. Additionally, that rising prevalence of chronic diseases will push the demand for singleplex immunoassay technologies.

Moreover, the growing awareness about immunoassay, enhanced focus on diagnostic testing, and increasing government assistance are continuously contributing to the growth of the global singleplex immunoassay market.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6196

Despite the drivers, some factors such as the stringent FDA regulations, the emergence of multiplex immunoassays, the complex procedure of testing, and poor healthcare system in low and middle-income countries may hamper the growth of the market to an extent.

Company Profiles:

Luminex

Thermo Fisher Scientific

Illumina

Bio-Rad Laboratories

QIAGEN N.V

Abcam

Becton Dickinson and Company

Merck Life sciences

Agilent Technologies

Quanterix

Bio-Techne

Olink

Seegene

BioVendor

Others

Segmentation:

The global singleplex immunoassay market is segmented on the basis of the product and service, type, technology, application, and end-user.

On the basis of the product and services, the market is classified as consumables, instruments, and others.

The global singleplex immunoassay market on the basis of the type is segmented as protein-based assays, nucleic acid-based assays, cell-based assays, and others.

On the basis of technology, the market is segmented into flow cytometry, fluorescence detection, and others.

The global singleplex immunoassay market, by application, is segmented into research and development, clinical diagnostics, and others. The research and development are further segmented into drug discovery & development and biomarker discovery and validation. The clinical diagnostics are further segmented into infectious diseases, cancer, cardiovascular diseases, autoimmune diseases, nervous system disorders, and metabolism & endocrinology disorders.

On the basis of the end-user, the global singleplex immunoassay market is segmented as pharmaceutical & biotechnology companies, hospitals & research institutes, reference laboratories and others.

Geographically, global singleplex immunoassay market has been segmented into America, Europe, Asia-Pacific, and the Middle East & Africa. The Americas singleplex immunoassay market is further segmented into North America, and South America. North America is further classified as the US and Canada.

The Europe singleplex immunoassay market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UKUK, Italy, Spain, and the Rest of Western Europe.

The Asia-Pacific singleplex immunoassay market is segmented into Japan, China, India, Republic of Korea, Australia, and Rest of Asia-Pacific.

The Middle East & Africa singleplex immunoassay market is segmented into the Middle East, and Africa.

Browse Full Copy @ https://www.marketresearchfuture.com/reports/singleplex-immunoassay-market-6196

Regional Market:

The global singleplex immunoassay market consists of four regions: Americas, Europe, Asia-Pacific and the Middle East & Africa. The Americas is expected to dominate the singleplex immunoassay market owing to the presence of major market players, high adoption rate, and increasing prevalence of infectious diseases. According to the statistics suggested by the Centers for Disease Control (CDC) and Prevention, in 2014, around 9,421 cases of tuberculosis, 51,455 cases of salmonella, 33,461 cases of Lyme disease, and 433 cases of meningococcal disease were registered in the United States.

Europe is anticipated to hold the second position in the global singleplex immunoassay market. It is expected that the rising automation in an immunoassay, increasing prevalence of chronic diseases, funding provided by the government, and private organizations towards research & development are anticipated to drive the European market.

The Asia-Pacific singleplex immunoassay market consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is the fastest growing in singleplex immunoassay market. Major factors such as growing patient pool, high incidence of chronic diseases, developing healthcare infrastructure and increasing research & development activities in the biotechnology sector, increasing healthcare expenditure influences the market in this region. Additionally, according to the data suggested by the Australian Institute of Health and Welfare during the year 2015-16, the total health expenditure was USD 170.4 billion, i.e., 3.6 % higher than the expenditure of 2014-2015.

The Middle East and Africa hold the least share in the global singleplex immunoassay market due to the presence of stringent government policies and poor economies. However, growing awareness among the population and high investments by private market players in this region can boost the market growth.

Ashu Kalbande Senior Web Marketing Executive at WiseGuy Research Future